Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation

American Journal of Cardiology

Volumn 103, Issue 6, 2009, Pages 824-828

  Bunch, T Jared ^a   Anderson, Jeffrey L ^a,b   May, Heidi T ^a   Muhlestein, Joseph B ^a,b   Horne, Benjamin D ^a,b   Crandall, Brian G ^a   Weiss, J Peter ^a   Lappé, Donald L ^a   Osborn, Jeffrey S ^a   Day, John D ^a  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DEATH; FEMALE; FRACTURE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OSTEOPOROSIS; PRIORITY JOURNAL;

ADULT; AGED; ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 61349095399     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.11.037     Document Type: Article

References (18)

1. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., et al., HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
2. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
3. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
4. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., Adami S., Fogelman I., Diamond T., Eastell R., Meunier P.J., Reginster J.Y., and Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
5. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., Chesnut III C.H., Brown J., Eriksen E.F., Hoseyni M.S., Axelrod D.W., and Miller P.D. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
6. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., Widmer A., Devogelaer J.P., Kaufman J.M., Jaeger P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653-661
7. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., Hyldstrup L., Recknor C., Nordsletten L., Moore K.A., et al., HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 (2007) 1799-1809
8. Cummings S.R., Schwartz A.V., and Black D.M. Alendronate and atrial fibrillation. N Engl J Med 356 (2007) 1895-1896
9. Early communication of an ongoing safety review. Bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa). http://www.fda.gov/Cder/Drug/early_comm/bisphosphonates.htm Accessed March 13, 2008
10. Sørensen H.T., Christensen S., Mehnert F., Pedersen L., Chapurlat R.D., Cummings S.R., and Baron J.A. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336 (2008) 813-816
11. Stafford R.S., Drieling R.L., and Hersh A.L. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 164 (2004) 1525-1530
12. Marcovitz P.A., Tran H.H., Franklin B.A., O'Neill W.W., Yerkey M., Boura J., Kleerekoper M., and Dickinson C.Z. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 96 (2005) 1059-1063
13. von der Recke P., Hansen M.A., and Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106 (1999) 273-278
14. Jorgensen L., Engstad T., and Jacobsen B.K. Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women. Stroke 32 (2001) 47-51
15. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., and Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32 (1998) 695-703
16. Crenshaw B.S., Ward S.R., Granger C.B., Stebbins A.L., Topol E.J., and Califf R.M. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 30 (1997) 406-413
17. Wong C.K., White H.D., Wilcox R.G., Criger D.A., Califf R.M., Topol E.J., and Ohman E.M. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 140 (2000) 878-885
18. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., and Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98 (1995) 476-484